GLPwatch
Semaglutide and the risk of diabetic retinopathy-current perspective.
Eye (Lond) · 2022
Last updated 2026-09-22| Journal | Eye (Lond), 2022 |
|---|---|
| Citations | 37 |
| Relative citation ratio | 3.15 |
| NIH percentile | 85 |
| Molecules | semaglutide |
| Conditions studied | Type 2 Diabetes |
Full record and abstract on PubMed 34373613 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.